A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy

This study has been terminated.
(For strategic buisness reasons.)
Sponsor:
Information provided by:
Myrexis Inc.
ClinicalTrials.gov Identifier:
NCT01026727
First received: December 2, 2009
Last updated: June 10, 2010
Last verified: June 2010
  Purpose

This phase 2b study is designed to assess the long-term efficacy (24 weeks) of MPC-4326 in combination with a 2-3 drug optimized background regimen (OBR) relative to the efficacy of a 3-4 antiretroviral (ARV) regimen in treatment experienced, HIV-1 infected subjects.


Condition Intervention Phase
HIV Infections
Drug: MPC-4326 plus a 2-3 drug optimized background regimen (OBR)
Drug: 3-4 commercially available antiretroviral drugs
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 2b Multicenter, Randomized, Open Label, Comparative Trial of MPC-4326 in Combination With a Two to Three Drug Optimized Background Regimen Versus an Optimized, Three to Four Drug Antiretroviral Regimen for the Treatment of Triple Class Antiretroviral Experienced, HIV-1 Infected Subjects Failing Current Therapy

Resource links provided by NLM:


Further study details as provided by Myrexis Inc.:

Primary Outcome Measures:
  • Proportion of subjects with a viral load <50 copies/mL at 24 weeks in each treatment group [ Time Frame: 24-weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • The key secondary endpoint is to compare the Viral Load Decrease at 24 weeks in the two treatment arms. VLD is defined as the change from baseline log10 viral load. [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 2
Study Start Date: November 2009
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MPC-4326 plus a 2-3 drug optimized background regimen (OBR)
MPC-4326 300 mg or 400mg BID plus a 2-3 drug optimized background regimen (OBR)for 24 weeks.
Drug: MPC-4326 plus a 2-3 drug optimized background regimen (OBR)
For treatment arm #1: the MPC-4326 dose will be selected based on the inclusion of raltegravir (i.e., will be limited to 300 mg BID) or inclusion of darunavir (i.e., will be assigned 400 mg BID) in the OBR. If both raltegravir and darunavir are included in the OBR for a subject, the subject will be limited to 300 mg BID
Active Comparator: 3-4 drug antiretroviral drugs
3-4 commercially available antiretroviral (ARV)drugs for 24 weeks.
Drug: 3-4 commercially available antiretroviral drugs
For treatment arm #2: the antiretroviral regimen, dosage and frequency will be selected by the investigator.

Detailed Description:

Standard antiretroviral therapies for the treatment of HIV/AIDS, while effective for varying lengths of time, can be rendered inadequate for viral suppression by the emergence of drug resistant virus, which can include resistance to entire mechanistic classes of drugs. Thus, there exists a significant unmet medical need for new highly potent antiretroviral agents with novel mechanisms of action. The novel mechanism of action of MPC-4326 suggests that MPC-4326 may have utility for the treatment of HIV-1 infected patients failing current regimens due to the development of drug resistance.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Voluntarily consent to participate in the study (sign Informed Consent Form), and able to understand study procedures and complete the study.
  2. Be at least 18 years of age at the time of screening.
  3. Have a screening plasma HIV-1 RNA value ≥ 1,000 copies/mL
  4. Be receiving an ARV regimen containing at least 3 drugs which has been unchanged for at least 8 weeks prior to initial screening.
  5. Have at least two fully active ARVs (exclusive of MPC-4326) as determined by a 'maximal response' on the vircoTYPE assay; R5 tropism testing (if applicable); and treatment history (e.g., naïve to enfuvirtide or integrase inhibitors) that can be combined in a regimen containing a maximum of four ARVs for the 3-4d ARV regimen or three ARVs for the 2-3-drug OBR to be combined with MPC-4326.
  6. Two NRTIs are not allowed as the only fully-active antiretroviral agents in the 3-4-drug ARV regimen or in the 2-3-drug OBR
  7. Must have wild type Gag at position 370 (i.e., no polymorphisms at 370)
  8. Have resistance to at least one agent in each of the three 'classic' ARV drug classes (NRTI, NNRTI, PI) to include documented evidence of resistance on prior resistance tests.
  9. Females of childbearing potential must agree to the use two forms of contraception from the time of screening until 90 days after completion of dosing.Surfactant-type spermicide gels and contraceptive foam are not recommended, as they increase the rate of HIV transmission.

Exclusion Criteria:

  1. Be pregnant or breast feeding
  2. Presence of any significant acute illness (as determined by the investigator) within 14 days of study entry.
  3. Presence of any AIDS-related opportunistic infection (Category C according to the CDC Classification System for HIV-1 Infection, 1993 Revised Version) that is unstable in the Investigator's opinion or diagnosed in the 30 days prior to study entry (i.e., Run in Period Day 1).
  4. A history of cerebrovascular accident or transient ischemic attacks.
  5. Subjects with the following laboratory parameters within 14 days prior to first dose of study drug:

    1. Hemoglobin < 10 g/dL for men and < 9 g/dL for women
    2. Absolute neutrophil count < 1000/mm3
    3. Platelet count < 50,000/mm3
    4. AST or ALT > 5 times the upper limit of normal inclusive of subjects with a positive HBV surface antigen or HCV antibody test at screening
    5. Calculated creatinine clearance (ClCr) <40 mL/min as determined by the Cockcroft-Gault equation
  6. Subjects who have received radiation therapy or cytotoxic chemotherapeutic agents within 4 weeks prior to the first dose of study drug.
  7. Subjects who have received treatment with immunomodulating agents such as IL-2, α IFN, β IFN or γ IFN within 4 weeks prior to the first dose of study drug.
  8. Subjects who use or require a prohibited therapy within 30 days prior to or while participating in this study.
  9. Receipt of an investigational drug or product, or participation in a drug study within a period of 30 days prior to receiving study medication. For investigational drugs with an elimination half life greater than 10 days, this period will be extended to 60 days and for antibody-based products (i.e., CD4 antibody products, etc.) this period will be extended to 3 months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01026727

  Hide Study Locations
Locations
United States, California
AIDS Healthcare Foundation Research Center
Beverly Hills, California, United States, 90211
Peter Wolfe, MD, PC
Los Angeles, California, United States, 90036
Quest Clinical Research
San Francisco, California, United States, 94115
United States, District of Columbia
Whitman Walker Clinic
Washington, District of Columbia, United States, 20009
United States, Florida
Therafirst Medical Center
Fort Lauderdale, Florida, United States, 33308
Gary J. Richmond, MD, PA
Fort Lauderdale, Florida, United States, 33316
Wohlfeiler, Piperato and Associates, LLC
Miami Beach, Florida, United States, 33139
Orlando Immunology Center
Orlando, Florida, United States, 32803-1851
United States, Georgia
AIDS Research Consortium of Atlanta
Atlanta, Georgia, United States, 30308
United States, Massachusetts
Community Research Initiative of New England
Boston, Massachusetts, United States, 2215
United States, New York
North Bronx Health Care Network
Bronx, New York, United States, 10461
University of Rochester , Strong Memorial Hospital
Rochester, New York, United States, 14642
United States, North Carolina
Duke University
Durham, North Carolina, United States, 27710
United States, Oregon
Kaiser Permanente Immune Deficiency Clinic
Portland, Oregon, United States, 97227
United States, Texas
Central Texas Clinical Research
Austin, Texas, United States, 78705
Southwest Infectious Disease
Dallas, Texas, United States, 75204
North Texas Infectious Disease Consultants, PA
Dallas, Texas, United States, 75246
Therapeutic Concepts, P.A
Houston, Texas, United States, 77004
DCOL Center
Longview, Texas, United States, 75605
United States, Virginia
CARE-ID
Annandale, Virginia, United States, 22003
United States, Washington
EHS Pulmonary & Critical Care
Spokane, Washington, United States, 99204
Canada, British Columbia
University of British Columbia,Downtown Infectuous Diseases Clinic
Vancouver, British Columbia, Canada, V6Z 2C7
Canada, Ontario
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
Canada, Quebec
Clinique médicale l'Actuel,
Montreal, Quebec, Canada, H2L 4P9
Clinique Médicale Quartier Latin
Montreal, Quebec, Canada, H2L 5B1
Sponsors and Collaborators
Myrexis Inc.
Investigators
Study Director: Andrew Beelen, MD Myrexis Inc.
  More Information

No publications provided

Responsible Party: Andrew Beelen, MD, Myriad Pharmaceuticals, Inc
ClinicalTrials.gov Identifier: NCT01026727     History of Changes
Other Study ID Numbers: MPC-4326-003.01
Study First Received: December 2, 2009
Last Updated: June 10, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Myrexis Inc.:
HIV Infections
Acquired Immunodeficiency Syndrome
Virus Diseases
Sexually Transmitted Diseases, Viral
RNA Virus Infections
Slow Virus Diseases
Immune System Diseases
Sexually Transmitted Diseases
Lentivirus Infections
Infection
Retroviridae Infections
Immunologic Deficiency Syndromes
HIV
treatment experienced
bevirimat

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases

ClinicalTrials.gov processed this record on August 20, 2014